Provided by Tiger Trade Technology Pte. Ltd.

Pfizer

27.78
-0.0100-0.04%
Post-market: 27.840.0593+0.21%19:59 EDT
Volume:29.14M
Turnover:810.84M
Market Cap:157.95B
PE:36.56
High:27.98
Open:27.76
Low:27.57
Close:27.79
52wk High:29.21
52wk Low:23.58
Shares:5.69B
Float Shares:5.64B
Volume Ratio:0.89
T/O Rate:0.52%
Dividend:1.72
Dividend Rate:6.19%
EPS(TTM):0.7599
EPS(LYR):1.36
ROE:5.01%
ROA:5.78%
PB:1.85
PE(LYR):20.36

Loading ...

Novartis India Hits Record High After Recent Acquisition, Distribution Deal

Reuters
·
2 hours ago

TwoStep Therapeutics Raises $62.5 Million in Series a Led by Insight Partners, Medical Excellence Capital

Reuters
·
14 hours ago

BMO Capital Adjusts Price Target on Pfizer to $35 From $30, Keeps Outperform Rating

MT Newswires Live
·
Yesterday

NYSE Most Active Issues

Dow Jones
·
Yesterday

Pfizer Inc. Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Yesterday

Pfizer CEO Bourla to Speak at Morgan Stanley Global Healthcare Conference Webcast

Reuters
·
Sep 08

The Second Act of Biotech

TIPRANKS
·
Sep 07

Novartis India to Acquire 'Minipress' Trademarks from Pfizer

Reuters
·
Sep 07

Pfizer Ramps Up Obesity And Eczema Bets, Investors Watch

TIPRANKS
·
Sep 05

Pfizer Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Sep 05

Pfizer’s Next Move in Obesity Drugs: What the New VESPER-JM Trial Means for PFE Investors

TIPRANKS
·
Sep 05

Pfizer Steps Up in Obesity Race With New Phase 3 Berobenatide Trial in Japan

TIPRANKS
·
Sep 05

Pfizer’s Tilrekimig Eczema Trial: A Fresh Phase 3 Catalyst for PFE Investors

TIPRANKS
·
Sep 05

Pfizer’s Migraine Tablet Study Wraps Up, Supporting Pipeline Flexibility for PFE Investors

TIPRANKS
·
Sep 05

Pfizer Announces Q3 2026 Dividend of R$ 0.37 Per Unit for Brpfizbdr 006

Reuters
·
Sep 03

Medicus Pharma Shares Down 20.5% Premarket; Co, Pfizer Enter Licensing Deal for Experimental Cancer Therapy

THOMSON REUTERS
·
Sep 03

Medicus Pharma Surges on Pfizer Licensing Deal for Experimental Cancer Therapy

Reuters
·
Sep 03

Medicus Pharma Signs Co-Development, Licensing Deal with Pfizer for Cd228v Antibody-Drug Conjugate

Reuters
·
Sep 03

Medicus Pharma - Pays Pfizer $12 Mln Upfront, $15 Mln Due on First Anniversary - SEC Filing

THOMSON REUTERS
·
Sep 03

Medicus Pharma - Pfizer Paid the Company a One-Time, Non-Refundable Payment of $2.0 Million

THOMSON REUTERS
·
Sep 03